What the DEA's 7-OH Scheduling Move Means for Buyers

On July 1, 2026, the DEA filed its intent to place concentrated 7-hydroxymitragynine and three related synthetic compounds into Schedule I — the first federal scheduling action against any kratom-derived substance ever to reach the Federal Register and survive its first week. Here is the plain-language version of what the agency did, the exact legal mechanics, the timeline from here, and what it means for ordinary kratom buyers.

The Two Notices, Precisely

The DEA filed two separate Notices of Intent on July 1, published in the Federal Register on July 6, 2026:

• FR Doc 2026-13580 covers 7-hydroxymitragynine above a specified threshold — including its isomers, esters, ethers, and salts. For botanical material of Mitragyna speciosa, the threshold is more than 0.050 percent 7-OH on a dry-weight basis; the notice also describes limits for non-botanical products. Material at or below natural trace levels is outside the action.
• FR Doc 2026-13581 covers three 7-OH-related substances: mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro-7-hydroxymitragynine (MGM-16) — synthetic or chemically modified compounds that have appeared in "enhanced" retail products and in forensic seizures.

Both notices proceed under 21 U.S.C. 811(h), the temporary scheduling provision. Temporary scheduling is the emergency lane of the Controlled Substances Act: it lets the DEA place a substance in Schedule I to avoid imminent hazard to public safety, for an initial period of up to two years (extendable by one more), while the full administrative scheduling process — with its formal rulemaking, scientific evaluation, and hearing rights — plays out separately. Before invoking it, the DEA must notify HHS; HHS responded that synthetic 7-OH and the three related substances have no currently accepted medical use and a high potential for abuse, and that it had no objection to the temporary placement.

The Evidence the DEA Cited

The Federal Register notices lay out the data behind the action. The FDA's adverse event reporting system (FAERS) recorded one 7-hydroxymitragynine case in 2023, two in 2024, then 66 in 2025 and 17 more in early 2026 — 86 total at the DEA's February 2026 query, of which 79 were serious and nine involved death. Poison control centers logged 1,690 kratom-related exposure calls from January to July 2025, a significant increase over 2024. The notices also cite forensic laboratory identifications of the synthetic compounds — MGM-15 appearing as a tan solid in New England, mitragynine pseudoindoxyl in pill and tablet form originating in Pennsylvania and Illinois — and the FDA's June 2025 warning letter to a concentrated-7-OH seller. HHS Secretary Robert F. Kennedy, Jr., who had earlier called 7-OH products "dangerous opioids," and the FDA publicly commended the action the day it was filed.

The through-line in the government's case: this is a product-category action, not a plant action. The FAERS spike tracks the retail explosion of concentrated tablets and shots, not traditional leaf — and the threshold design reflects exactly that distinction, as we cover in depth in our 7-OH vs natural leaf pillar.

The Timeline From Here

Until an order issues, the notices signal intent rather than impose control. Once an order takes effect, every Schedule I consequence attaches to the covered substances: manufacture, distribution, import, export, research handling, and possession above the threshold all fall under federal criminal law, with registration requirements for any legitimate research.

What It Means for Buyers

• Natural leaf is untouched federally. Ordinary botanical kratom with trace 7-OH below 0.050 percent dry weight remains unscheduled. State law still governs — nine states ban kratom outright regardless of this action.
• Concentrated 7-OH products are ending. Tablets, shots, and gummies marketed on 7-OH content are the covered category. Retailers began clearing them ahead of the effective date; anything still on a shelf after the orders land is a federal problem for everyone in the chain.
• COAs are now compliance documents. The alkaloid panel on a certificate of analysis is where the 0.050 percent question gets answered. Vendors that publish batch-level alkaloid data — the standard we apply across our vendor screen — were built for this rule before it existed.
• The comment docket is real input. The 2016 scheduling attempt died on public comment and congressional pressure; HHS soliciting threshold input through July 31 (docket HHS-OASH-2026-0232 at regulations.gov) is the formal channel this time.

What Schedule I Actually Means Here

A common misreading is worth heading off: Schedule I placement does not merely restrict retail sale. Once the temporary orders take effect, every activity involving the covered substances — manufacturing, distributing, reverse-distributing, importing, exporting, conducting research or chemical analysis, and simple possession above the threshold — requires DEA registration or becomes a federal crime. For the concentrated-product industry that grew up between 2023 and 2025, that is an extinction-level rule, not a compliance burden. For researchers, it means 7-OH studies above the threshold will need Schedule I research registrations — a genuine friction that scientists on both sides of the kratom debate have flagged, since the compound's pharmacology is exactly what the permanent-scheduling review will eventually need to evaluate.

How This Differs From 2016

Veterans of the 2016 fight will remember the DEA's announced intent to schedule mitragynine and 7-OH wholesale — an action that would have federally banned all kratom — and its unprecedented withdrawal after tens of thousands of comments and bipartisan congressional letters. The 2026 action is engineered around that history. It schedules no mitragynine. It leaves leaf below the threshold alone. It targets the concentrated-product category whose adverse-event data supplied the imminent-hazard finding. And it arrives with HHS and FDA publicly aligned rather than out in front. Whether one reads that as regulatory precision or as a first installment, the design tells you the agencies studied why the last attempt failed.

What could still change the picture: the comment docket could move the threshold; litigation could test the temporary order; the pending Ricketts-led Senate push for broader FDA scheduling could revive the 2016-style fight; and the permanent-scheduling process will eventually demand the full scientific review the temporary lane defers. We track all of it in the 2026 regulation landscape.